

1118

POSTER

Neoadjuvant radiotherapy for locally advanced rectal carcinoma: results of two treatment schedules

H. Kranzbühler, G. Gruber, R.H. Greiner. ¹ *Inselspital, Radiation-Oncology, Berne, Switzerland*

Objective: To evaluate the outcome of pre-op accelerated-hyperfractionated RT and RT plus simultaneous chemotherapy (CTX) for advanced rectal cancer.

Patients and methods: From 5/95 to 12/99 a total of 55 pts (median age 64y) were treated pre-op. Group 1 (n=35): RT alone (TD 25Gy, SD 2.5Gy bid) for pts with primarily resectable cT2-4cN0-2M0 adenoca. Group 2 (n=20): RT (minimal TD 45Gy/SD 1.8Gy/25Fx/5 weeks) plus 2 cycles of simultaneous 5-FU (1g/m² PVI d1-5 and d29-33) for pts with primarily unresectable cT3-4cN0-2M0. In node positive patients post-op 5-FU/Leucovorin was administered. Median follow-up was 23 months.

Results: All pts of group 1 underwent surgery (R0: 89%) with sphincter sparing procedure (SSP) in 22/35 pts; resection rate in group 2 was 80% (R0: 88%, SSP 8/16 pts). LRFS, DFS, CSS and OS at 36 months were 93%, 87%, 91%, 87% (group 1) and 83%, 55%, 62% and 54% (group 2) respectively. Negative prognostic factors for outcome were positive margins (p=0.009), T4 vs T2/3 (p=0.045), low tumour site (p<0.1) and N2 (p<0.1). 4 pts with histologically proven complete remission (pCR) following combined treatment were NED after a median follow-up of 38 months.

Conclusions: The goal of complete resection can be achieved in the majority after pre-op RT or RT+CTX with promising results regarding local control and survival. Pts with pCR following RCT carry a favourable prognosis.

1119

POSTER

Preoperative chemoradiotherapy improves downstaging and survival in advanced rectal cancer

B. Amsler, R. Kann, B. Opferkuch, C. Landmann. *University Hospital Basel, Radiation Oncology, Basel, Switzerland*

Objective: Locally advanced tumors of the rectum show a high incidence of local recurrence and can often not be operated by sphincter sparing procedures. The impact of preoperative chemoradiation on resectability, local control and survival rates is analysed.

Methods and materials: In the years 1994 to 2000 51 patients (35 men, 16 women) with a median age of 62 years (range 24-83) were treated with preoperative chemoradiation. The tumorstages were uT3 (N=36), uT4 (N=15), cN1 (N=18) and cN2 (N=1). Distribution according to histological grade was G1 5, G2 32, G3 5 and Gx 9 cases. 61% (31/51) of the patients had a tumor located closer than 6cm to the anus and were considered critical for sphincter sparing surgery. Almost all patients (47/51) received a simultaneous chemotherapy with 5-FU which was administered in 8 different oncology centers. A continuous 5-FU infusion with a dose of 200 or 225 mg/m²/day over 5 weeks was applied in 82% of cases. Radiation was administered with a 3 field technique encompassing the whole pelvis with the patient lying prone on a belly board. All patients received a total dose of 45Gy in 1.8Gy daily fractions. Surgery was carried out 13-74 days (median 31 days) after the end of chemoradiation.

Results: All patients finished chemoradiation as planned in a median time of 35 days (range 31-39 days). All patients except for 2 (1 refused, 1 lost to follow-up) were operated. In 30 cases a sphincter sparing resection was possible, among those were 12 patients with a tumor closer than 6cm to the anus. 19 patients underwent abdominoperineal resection. The resection was R1 in 3 and showed close margins in 4 cases. Pathological downstaging was achieved in 59% for T stage and in 24% for N+ stage. Downstaging of the primary to pT0 was found in 20% of cases. Upstaging occurred in 7 cN0 cases to pN1 and in 2 patients to pM1 (liver). Estimated 5 year overall-survival (according to Kaplan-Meier) was 90% and disease-free survival 70%. In 9 patients local and/or distant recurrence was documented.

Conclusion: Simultaneous radiation and 5-FU is well tolerated and allows for significant downstaging in rectal cancer resulting in excellent survival rates. It furthermore enables sphincter sparing surgery in distal tumors. Close or positive margins are found to be a negative prognostic factor.

1120

POSTER

Tumor suppressor gene nm23-H1 in sporadic colon adenocarcinoma

S. Kapitanovic¹, T. Cacev¹, S. Radosevic², K. Pavelic¹, R. Spaventi^{1,2}. ¹ *Rudjer Boskovic Institute, Division of Molecular Medicine, Zagreb, Croatia;* ² *PLIVA d.d., Research & Development, Zagreb, Croatia*

The discovery of genetic alterations in oncogenes and tumor-suppressor genes, which accompany tumor formation in a wide variety of human tumor types, has encouraged the search for genes that may promote or suppress tumor spread and metastasis. Nm23 gene was originally identified by differential hybridisation of K-1735 melanoma cell line clones of varying metastatic potential. A tumor metastases-suppressor function was implicated by the reduced expression of nm23 in highly metastatic sublines compared with non-metastatic sublines derived from the same K-1735 clone.

Nm23 expression has been shown to be higher in several different tumors of lower metastatic potential than in the corresponding tumors of higher metastatic potential, including breast, hepatocellular, ovarian and gastric carcinomas and melanoma. In other tumors, such as neuroblastoma, pancreatic carcinoma and head and neck carcinomas, surprisingly, the opposite trend has been reported.

The purpose of this study was to evaluate whether the expression of the nm23-H1 protein or loss of heterozygosity (LOH) of the nm23-H1 gene is associated with tumor stage and grade of tumor differentiation. In addition, we also investigated the correlation of nm23-H1 expression with 5-year survival.

Paraffin tissue sections were analyzed immunohistochemically using monoclonal antibody NM301 to human nm23-H1 protein. DNAs (normal and tumor) isolated from microdissections of paraffin sections were used for LOH analysis.

Of 102 adenocarcinomas that were examined, 41% showed a weak positive immunostaining for nm23-H1 protein. The most nm23-H1 positive tumors were in Dukes' B (67%) and in the well differentiated tumors (65%). Statistical analysis showed that there was no statistically significant difference in survival between the patients with nm23-H1 positive tumors and patients with tumors that were not stained for nm23-H1 protein.

To analyze LOH at the nm23-H1 gene we used VNTR marker located in untranslated 5' region of the nm23-H1 gene. At this nm23-H1 locus 60% of samples were informative and 33% of them demonstrated LOH. The nm23-H1 LOH was more frequent in tumors that were larger than 5 cm than in smaller ones. Positive correlation was found between the nm23-H1 LOH and histological grade of tumors. Positive correlation was also found between the nm23-H1 LOH and Dukes' stage of tumor samples.

1121

POSTER

Expression of tumour associated antigens in colorectal cancer

M.V. Croce, A.G. Colussi, E. Adigogovic, A. Segal-Eiras. *Faculty of Medicine, CINIBA, La Plata, Argentina*

Purpose: The relationship of tumour-associated antigens with colorectal carcinoma was studied by immunohistochemistry with a panel of monoclonal antibodies (MAbs).

Materials and Method: Tumour tissue samples were obtained from 24 patients with colorectal cancer (Duke's stages B, C and D) and five patients with benign colorectal conditions. Immunohistochemistry was performed following standard procedures; the tumour associated antigens included: carcinoembryonic antigen (CEA, C365 MAb), colonic glycolipid (C505 MAb), normal colorectal antigen (NCA, C198 MAb), Lewis x (KM380 MAb), sialyl Lewis x (KM93 MAb), Lewis y (C14 MAb), Tn hapten (83D4 MAb) and MUC1 (C595 MAb). Immune reaction was graded according to positive staining, intensity and distribution; staining intensity was scored in grades: negative, low, moderate and strong.

Results: In colorectal cancer tissue sections, a high expression of tumour antigens was found being colonic glycolipid the most frequently observed (79% positive sections/total); NCA reacted in 76%; CEA in 75%. MUC1 was positive in 67% while sialyl Lewis x was detected in 53%; Lewis x and Lewis y in 44% and Tn in 30%. Some samples showed a remarkable positive expression of glycolipid antigen, NCA, CEA and Lewis x; Lewis y showed a moderate staining; an interesting feature was the expression of MUC1 in invasive areas of several specimens. The other antigens showed a weak and restricted reaction. Tissue samples from benign colorectal conditions reacted weakly although occasionally a strong immune staining was observed; the pattern of reaction was always restricted to some areas of the section.

Conclusion: Colorectal cancer expresses strongly a variety of tumour antigens which are involved in recurrence and metastatic processes

1122

POSTER

The value of follow-up in resectable colo-rectal cancer after adjuvant therapy

A. Urruticoechea¹, M. Navarro¹, M. Majem¹, L. Pareja², J. Martí-Ragué³, J. Figueras³, M. Galán¹, J. Germá¹. ¹Institut Català d'Oncologia, Medical Oncology, Barcelona, Spain; ²Institut Català d'Oncologia, Cancer Epidemiology Department, Barcelona, Spain; ³Ciutat Sanitària de Bellvitge, Surgery Department, Barcelona, Spain

The aim of post-operative follow-up in colo-rectal cancer (CRC) patients (pts) is to detect recurrences while resectable with the possibility of improving survival. Benefit in long-term survival is still controversial while exhaustive follow-up is expensive and bothersome for patients.

Methods: Between 1993 and 1997 we followed up 399 pts (225 males, 174 females) with resectable CRC (207 colon, 192 rectum) after adjuvant therapy. The mean age was 59 years (33-78). Pathological stages: Colon: EII 65, EIII 142; rectum: EII:81, EIII:111. Adjuvant treatment: the main schedule in colon cancer was Levamisole + 5-Fluorouracil (Lev + 5FU) in 87%, and in rectum was 5FU (500 mg/sqm/day x 5d every 4 w x 8 cycles) in 85% + pelvic radiotherapy in 98%. The follow-up consisted on: CEA and clinical examination every 3 months(m) the first 2 years, every 4 m the third year, every 6 m the 4th and 5th year and annually thereafter; abdominal ultrasonography (AUS) every 6 m for the first two years and yearly afterwards; chest roentgenogram annually; colonoscopy every 2 years; rectoscopy annually the first 2 years and abdominal CT scan at 12 and 24 m in rectum. If CEA elevations were detected, cross-sectional imaging was done. Mean of follow-up was 48 m.

Results: Recurrences were detected in 126 of 377 evaluable pts (4 lost of follow-up while free of disease and 18 deaths for other reasons): 16 locoregional (L), 94 systemics (S) and 16 L+S. The 86.4% of those were detected within the first 3 years. The main indicator of recurrence was: CEA in 84 pts (64%), CT in 12pts (9.6%) and clinical in 19 pts (15.2%). 39 pts (31%) underwent rescue surgery for recurrent disease: 6 L (37.5%); 31 S (32.9%); 2 L+S (12.5%). From the total of recurrences 38 involved liver as unique site, from these, 23 (61%) underwent rescue surgery. At the end of this study (Feb 01) 19 pts are still alive: 12 (30.7%) free of disease and 7 (17.9%) with a 2nd recurrence. Median of survival when rescue surgery was performed was 35m (16.2-53.8) versus 11m (8-14) when it was not possible ($p < 0.001$).

Conclusions: Postoperative follow-up in CRC with high risk of recurrence is useful, specially in the first three years. With a less exhaustive follow-up based in CEA, clinical examination and a rational postoperative imaging, we have achieved a great number of rescuable recurrences and an obvious benefit in time of survival in these patients

1123

POSTER

Association of p27 and TGF- β expressions with colorectal cancer: an immunohistochemical study

S. Erdamar¹, H. Tuncel², I. Celikbas¹, G. Dogusoy¹, S. Goksel¹, S. Gocener¹. ¹Istanbul University Cerrahpasa Medical Faculty, Pathology, Istanbul, Turkey; ²Istanbul University Cerrahpasa Medical Faculty, Biophysics, Istanbul, Turkey

Introduction: TGF- β 1 has been demonstrated to be an inhibitor epithelial cell growth and it is commonly over expressed in solid malignancies. Down regulation of p27, a cyclin dependent kinase inhibitor is associated with aggressive behavior in some tumors. We analyzed immunohistochemically TGF-beta and p27 expression levels in human colorectal carcinomas associated with inflammatory bowel diseases e.g. colitis ulcerosa (CU) and polyposis coli.

Methods: Formal in fixed-paraffin embedded sections from randomly selected 15 CU cases with epithelial dysplasia in various degrees, 25 colorectal adenocarcinoma (Cca) arise in polyposis coli (PC) were immunostained with a monoclonal antibody against TGF-beta and p27 proteins immunoactivity was evaluated without any clinico-pathologic knowledge. p27 analysis was recorded as p27 labeling index. TGF-beta analysis was revealed as intensity of staining, (+/+++).

Results: There were not any significant differences in TGF-beta levels in normal epithelia and CU group. It's found significant TGF-beta over expression in Cca group ($p < 0.05$). The p27 labeling index in normal colorectal mucosal epithelia was 94.3% \pm 3.2% (meanSD), and in UC was 68.3% \pm 5.4% ($p < 0.05$). It was also found significantly reduced p27 expression in Cca

group (25.05% \pm 8.5%) and PC group (41.07% \pm 2.6%) ($p < 0.05$). Reduced p27 expression and TGF-beta over expressions were associated with invasion level and histological grade in Cca group.

Conclusion: This study showed that the posttranslational reduction of levels of p27kip1, which mediates TGF-beta growth inhibition, provides an additional means for colorectal adenocarcinoma cells to escape negative growth regulation by TGF-beta.

1124

POSTER

A phase II study of irinotecan (CPT-11) alternated with a weekly schedule of oxaliplatin (L-OHP), high-dose leucovorin (LV) and a 48-hour infusion 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer (MCR)

G. Rosati¹, A. Tucci², A. Rinaldi³, D. Colarusso⁴, A. Rossi¹, C. Pizzi², L. Manzione¹. ¹Division of Medical Oncology, "S. Carlo" Hospital of Potenza; ²Division of Medical Oncology, Civil Hospital of Nola; ³Division of Medicine, Civil Hospital of Castellana; ⁴Division of Medicine, Civil Hospital of Lagonegro, Italy

Purpose: In an our previous phase II study we have verified that the efficacy of CPT-11 alternated with a weekly-times-four schedule of high-dose LV and a 48-hour infusion 5-FU is comparable to that of regimens with drugs given together, but at lower costs and less toxicity (data in press). In order to improve the infusional part results of regimen, we conducted a phase I trial in which a weekly administration of L-OHP was added (Ann Oncol, in press).

Methods: We tested the activity of a regimen consisting of a weekly-times-four schedule of L-OHP (65 mg/m²), high-dose LV (150 mg/m²) followed by a 48-hour 5-FU infusion (2300 mg/m²) alternated with CPT-11 (350 mg/m²). A cycle was to be performed every eight weeks. Twenty-five consecutive patients (M/F, 12/13) with measurable MCR, aged 26-74, PS (ECOG): 0/1/2, 8/15/2 entered our study. Metastatic sites: liver (64%), lung (24%) and lymph nodes (16%).

Results: All patients were evaluable for toxicity and 15 for response. The objective response rate was 47% (7 of 15 patients; 1 complete and 6 partial responses). An additional 53% of the patients had stable disease. After a median number of 3 cycles per patient no toxic deaths occurred. The incidence of grade 3-4 toxicity per patient in any cycle was: mucositis 8%, and diarrhea 40% for the infusional part; diarrhea 4% and neutropenia 24% for the CPT-11 part of regimen. No patient stopped the treatment due to neurotoxicity.

Conclusions: These preliminary results suggest that our schedule is feasible and highly active: the overall tumor growth control rate is 100%. The reported data stimulate us to continue the study and up-dated results will be presented.

1125

POSTER

Elevated serum VEGF levels in colorectal cancer patients correlate with poor survival

A. Karayiannakis¹, K. Syrigos², A. Zbar³, N. Baibas², D. Tsioulos², A. Polychronidis¹, C. Simopoulos¹, G. Karatzas⁴. ¹Democritus University of Thrace, 2nd Department of Surgery, Alexandroupolis, Greece; ²Athens Medical School, 3rd Department of Medicine, Athens, Greece; ³Kaplan Medical Center, Department of Surgery, Rehovot, Israel; ⁴Athens Medical School, 2nd Department of Surgery, Athens, Greece

Purpose: Vascular endothelial growth factor (VEGF) is an angiogenic cytokine involved in tumor progression and metastasis. In this study, we evaluated the clinical usefulness of circulating VEGF concentrations in colorectal cancer.

Methods: Serum VEGF concentrations were determined in the sera of 61 healthy controls and 67 patients with colorectal cancer by an enzyme linked immunosorbent assay and associated these levels with clinicopathological features and patient survival.

Results: Colorectal cancer patients showed significantly higher serum VEGF levels compared with healthy controls. Serum VEGF levels correlated significantly with degree of tumor differentiation, disease stage, tumor invasion depth, and the presence of lymph node and distant metastases. Univariate analysis showed significantly lower survival rate for patients with elevated serum VEGF levels. Multivariate regression analysis showed that the prognostic value of serum VEGF level was not independent of tumor stage.

Conclusion: Serum VEGF levels in colorectal cancer patients reflect the presence of advanced and metastatic tumor and their determination might be clinically useful.